The Journal of Infectious Diseases
Oxford University Press
image
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
DOI 10.1093/infdis/jiaa228
  • XML   
  •       

Highlights

Notes

Abstract

Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.

Keywords
Zeng, Yu, Gou, Li, Ma, Zhang, Xu, Lin, Cui, Zhang, Li, Wang, Zhang, and Liu: Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
https://www.researchpad.co/tools/openurl?pubtype=article&doi=10.1093/infdis/jiaa228&title=Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients&author=Qing-Lei Zeng,Zu-Jiang Yu,Jian-Jun Gou,Guang-Ming Li,Shu-Huan Ma,Guo-Fan Zhang,Jiang-Hai Xu,Wan-Bao Lin,Guang-Lin Cui,Min-Min Zhang,Cheng Li,Ze-Shuai Wang,Zhi-Hao Zhang,Zhang-Suo Liu,&keyword=Convalescent plasma therapy,Coronavirus disease 2019 (COVID-19),Fatality,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),Survival rate,Viral shedding,&subject=Brief Report,AcademicSubjects/MED00860,AcademicSubjects/MED00290,